Allegro Completes Enrollment for Validation Trial for BronchoGen Lung Cancer Risk Test, Anticipates Release in 2013 | GenomeWeb

The headline for this story has been updated from a previous version to clarify that the company has completed enrollment for the trial.

Allegro Diagnostics announced last week that it has completed enrollment of a trial it hopes will provide additional validation of its BronchoGen lung cancer diagnostic ahead of a launch early next year, as well as provide clinical utility data to support future reimbursement discussions.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.